Taiko Pharmaceutical Co.,Ltd.

TSE:4574.T

309 (JPY) • At close June 30, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) JPY.

2024202320222021202020192018201720162015201420132012201120102009200820072006
Revenue 6,2926,1205,04010,72017,683.98914,936.16510,377.6469,438.3668,284.8878,295.2889,237.7749,868.2877,415.7436,690.8124,470.4248,733.4336,091.3235,542.124,935
Cost of Revenue 2,6263,5433,9617,9735,263.1294,357.7933,215.8122,885.8922,713.9942,556.2552,354.7762,683.6592,407.8422,201.4731,584.2152,437.6481,644.2751,588.8791,265
Gross Profit 3,6662,5771,0792,74712,420.8610,578.3727,161.8346,552.4745,570.8935,739.0336,882.9987,184.6285,007.9014,489.3392,886.2096,295.7854,447.0483,953.2413,670
Gross Profit Ratio 0.5830.4210.2140.2560.7020.7080.690.6940.6720.6920.7450.7280.6750.6710.6460.7210.730.7130.744
Reseach & Development Expenses 183245000041000000000000122
General & Administrative Expenses 0000003,1894,695.42300000000000
Selling & Marketing Expenses 0000001,942000000000000
SG&A 2,8533,58300005,1314,695.42300000000003,039
Other Expenses -3-2464,1577,6946,769.871-282.124-188.136-249.06-182.427-22.86221.24121.90514.48931.81888.4522.265-10.45656.7480
Operating Expenses 3,0373,5824,1577,6946,769.8716,753.7925,131.9074,695.4234,025.4884,391.3354,323.7764,593.843,886.9033,974.3354,128.7753,806.5683,552.6763,281.0963,161
Operating Income 629-1,005-3,079-4,9485,650.9873,824.5782,029.9261,857.051,545.4051,347.6962,559.2212,590.7871,120.997515.003-1,242.5652,489.216894.371672.144519
Operating Income Ratio 0.1-0.164-0.611-0.4620.320.2560.1960.1970.1870.1620.2770.2630.1510.077-0.2780.2850.1470.1210.105
Total Other Income Expenses Net -64-2,558-1,790-3,939-276.717-320.253-45-304.305-54.374-156.171199.397-37.115-20.436-100.452-753.326100.29-203.256-72.473227
Income Before Tax 565-3,563-4,869-8,8875,374.273,504.3261,985.9831,552.7451,491.0311,191.5252,758.6182,553.6721,100.561414.551-1,995.8922,589.506691.115599.671746
Income Before Tax Ratio 0.09-0.582-0.966-0.8290.3040.2350.1910.1650.180.1440.2990.2590.1480.062-0.4460.2970.1130.1080.151
Income Tax Expense -33247257061,522.7111,050.859570.491457.786441.614351.414988.075806.43963.035-67.652232.316944.383220.338239.232367
Net Income 898-3,611-4,894-9,5933,851.5592,453.4661,415.4911,094.9591,049.416840.111,770.5411,747.2331,037.525482.204-2,228.2081,645.122470.777360.439379
Net Income Ratio 0.143-0.59-0.971-0.8950.2180.1640.1360.1160.1270.1010.1920.1770.140.072-0.4980.1880.0770.0650.077
EPS 17.89-76.25-112.24-220.4889.1857.573325.825.4821.7446.3145.3127.112.41-57.8542.9912.337.8440.15
EPS Diluted 17.89-76.25-112.24-220.4888.8257.3432.9625.6925.2721.2844.8243.8526.712.17-57.8540.8312.337.8440.15
EBITDA 882-2,851-3,750-5,5685,923.5124,066.0362,389.8952,325.8661,906.8881,660.8382,857.5392,979.4451,482.6918.23-197.7382,643.8471,223.525833.255911
EBITDA Ratio 0.14-0.466-0.744-0.5190.3350.2720.230.2460.230.20.3090.3020.20.137-0.0440.3030.2010.150.185